1. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). (September 2015) Authors: Hodi, F.S.; Gibney, G.; Sullivan, R.; Sosman, J.A.; Slingluff, C.L.; Lawrence, D.P.; Logan, T.F.; Schuchter, L.M.; Nair, S.; Fecher, L.; Buchbinder, E.; Ruisi, M.; Kong, G.; Horak, C.; Weber, J.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗